Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Shares Outstanding (Weighted Average) (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $171.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 20.1% to $171.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $171.6 million, a 20.1% increase, with the full-year FY2025 number at $171.6 million, up 20.1% from a year prior.
  • Shares Outstanding (Weighted Average) was $171.6 million for Q4 2025 at Relay Therapeutics, roughly flat from $171.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $171.6 million in Q4 2025 to a low of $90.2 million in Q1 2021.
  • A 5-year average of $126.3 million and a median of $121.7 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 2071.45% in 2021, then rose 7.85% in 2024.
  • Relay Therapeutics' Shares Outstanding (Weighted Average) stood at $95.1 million in 2021, then grew by 17.97% to $112.2 million in 2022, then increased by 9.22% to $122.6 million in 2023, then rose by 16.55% to $142.9 million in 2024, then grew by 20.1% to $171.6 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Shares Outstanding (Weighted Average) are $171.6 million (Q4 2025), $171.0 million (Q3 2025), and $171.3 million (Q2 2025).